首页> 外文OA文献 >Birdshot uveitis: current and emerging treatment options.
【2h】

Birdshot uveitis: current and emerging treatment options.

机译:鸟状葡萄膜炎:当前和新兴的治疗选择。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Birdshot chorioretinopathy is a relatively uncommon subtype of idiopathic posterior uveitis with distinct clinical characteristics and a strong genetic association with the Human Leukocyte Antigen (HLA)-A29 allele. The diagnosis remains clinical and is based on the presence of typical clinical features, including multiple, distinctive, hypopigmented choroidal lesions throughout the fundus. The long-term visual prognosis of this disorder, however, remains guarded - central visual acuity can be preserved until late in the disease and it is not uncommon for patients to receive inadequate immunosuppressive treatment, leading to a poor long-term outcome in which peripheral retinal damage eventually leads to visual deterioration. Birdshot chorioretinopathy has proven a particularly attractive area of study within the field of uveitis, as it is a relatively easily defined disease with an associated human leukocyte antigen haplotype. Despite this, however, the immune mechanisms involved in its pathogenesis remain unclear, and some patients continue to lose retinal function despite therapy with corticosteroids and conventional immunosuppressive agents. Laboratory research continues to investigate the underlying mechanisms of disease, and clinical research is now being driven to improve the phenotyping and monitoring of this condition as, in the era of so-called personalized medicine, it is becoming increasingly important to identify patients at risk of visual loss early so that they can be treated more aggressively with targeted therapies such as the newer biological agents. This approach requires the formation of collaborative groups, as the relative rarity of the condition makes it difficult for one center to accumulate enough patients for worthwhile studies. Nevertheless, results obtained with newer therapies, such as biological agents directed against particular cytokines or cell-surface receptors, demonstrate ever improving control of the inflammation in refractory cases, providing hope that the outlook for visual function in this condition can only improve.
机译:鸟状脉络膜视网膜病变是特发性后葡萄膜炎的一种相对罕见的亚型,具有独特的临床特征,并且与人类白细胞抗原(HLA)-A29等位基因有很强的遗传联系。诊断仍然是临床的,并且基于典型的临床特征的存在,包括整个眼底多个,独特的色素沉着的脉络膜病变。但是,该疾病的长期视觉预后仍然受到保护-中心视力可以保留到疾病晚期,而且患者接受免疫抑制治疗不足的情况并不罕见,导致外周血的长期不良预后。视网膜损伤最终导致视觉恶化。鸟状脉络膜视网膜病已被证明在葡萄膜炎领域是一个特别有吸引力的研究领域,因为它是一种相对容易定义的疾病,伴有相关的人类白细胞抗原单倍型。然而,尽管如此,其发病机理中涉及的免疫机制仍不清楚,尽管使用皮质类固醇和常规的免疫抑制剂治疗,一些患者仍会丧失视网膜功能。实验室研究继续研究疾病的潜在机制,现在正推动临床研究来改善这种疾病的表型和监测,因为在所谓的个性化医学时代,识别有感染风险的患者变得越来越重要。尽早消除视力,以便可以使用靶向疗法(例如新型生物制剂)更积极地治疗它们。这种方法需要组建协作小组,因为这种病的相对罕见性使得一个中心很难积累足够的患者进行有价值的研究。然而,使用新疗法(例如针对特定细胞因子或细胞表面受体的生物制剂)获得的结果表明,在难治性病例中炎症控制得到了不断改善,这希望这种状况下的视觉功能只能改善。

著录项

  • 作者

    Menezo, V; Taylor, SR;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号